# Cimeio Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cimeio-therapeutics

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.cimeio.com
- Total disclosed funding: $50M
- Latest round: Series A (Apr 13, 2022)
- Investors on record: 1

## About

Based in Switzerland, and founded in 2020 by Lukas Jeker, Cimeio Therapeutics AG, aka Cimeio, is a patented technological platform working to produce curative medications for people with genetic ailments, hematologic malignancies, and severe autoimmune disorders. In April 2022, Cimeio Therapeutics AG, led by its CEO Thomas Fuchs, raised USD 50 million in series A funding led by new investor Versant Ventures.

The business intends to use the funds raised in 2022 to continue to change and develop medical options for rare congenital disorders. The firm will begin clinical trials on its initial projects in 2023.

## Funding rounds

- Series A, Apr 13, 2022, $50M — Versant Ventures

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A